Sajith Wickramasekara is the co-founder and CEO of Benchling, a leading biotech R&D software company. Under his leadership, Benchling has grown to serve over 600 customers, including major biotech firms, and is valued at $6.1 billion.
Who is the CEO of Benchling?
With a background in computer science from MIT, Sajith Wickramasekara co-founded Benchling in 2012, driven by a vision to revolutionize biotech R&D. Recognizing the inefficiencies in traditional research methods, he aimed to create a platform that would bridge the gap between software engineering and biological research. Under his leadership, Benchling has grown significantly, serving over 600 customers globally and achieving a valuation of $6.1 billion.
His innovative approach has earned him a spot on the Forbes 30 Under 30 Hall of Fame, highlighting his impact on the industry.
Work History
Before founding Benchling, Sajith Wickramasekara gained valuable experience in various research roles. His work history includes:
- Benchling - Founder & CEO (2012 - Present)
- Liquidia Technologies - Research Assistant (2009)
- Duke University Medical Center - Research Assistant (2007 - 2009)
Education History
Sajith Wickramasekara's educational journey began at the North Carolina School of Science and Mathematics, a prestigious institution known for nurturing young talent in the sciences. He then advanced to the Massachusetts Institute of Technology (MIT), where he pursued a degree in Electrical Engineering and Computer Science. This rigorous academic background provided him with a strong foundation in both theoretical and practical aspects of technology, which later played a crucial role in his ability to innovate within the biotech industry.
When did Sajith Wickramasekara join Benchling?
Sajith Wickramasekara co-founded Benchling in 2012, marking the beginning of his journey with the company. As the founder, he has been the CEO since its inception. Over the years, his leadership has been instrumental in driving the company's growth and innovation.
Having been with Benchling for approximately 12 years, Wickramasekara continues to play a pivotal role in shaping the future of biotech R&D.